|
|
TuM2-PK检测在消化道肿瘤中的应用价值
|
Abstract:
食管、胃、结直肠等部位的肿瘤总称为消化道肿瘤，由于早期消化道肿瘤患者没有明显的临床症状，从而导致就诊时基本都是肿瘤的中晚期，因此治疗效果差，预后欠佳。大量的研究和临床数据证实，预防和降低死亡率最有效的办法就是早诊断、早治疗。肿瘤的发生、发展与肿瘤标记物的表达水平在一定程度上显示相关性，因此，寻找可用于早期诊断和预后判断的肿瘤标志物一直是人们关注的焦点。M2型丙酮酸激酶(pyruvate kinase isoenzyme type M2, PKM2)是糖酵解过程中的限速酶丙酮酸激酶的同分异构体中的一种，可通过瓦伯格效果促进肿瘤细胞的生长与增值，是肿瘤能量代谢的重要标志，是一种潜在的新型肿瘤标记物，作者对其进行了综述和梳理。
Tumors of the esophagus, stomach, colorectum and other parts are collectively called gastrointesti-nal tumors, because patients with early gastrointestinal tumors have no obvious clinical symptoms, resulting in the middle and advanced stages of the tumor at the time of treatment, so the treatment effect is poor and the prognosis is poor. A large number of studies and clinical data confirm that the most effective way to prevent and reduce mortality is early diagnosis and early treatment. The oc-currence and development of tumors and the expression level of tumor markers show a correlation to a certain extent, so the search for tumor markers that can be used for early diagnosis and prog-nosis judgment has always been the focus of attention. M2 type pyruvate kinase isoenzyme type M2 (PKM2) is an isomer of the rate-limiting enzyme pyruvate kinase during glycolysis, which can pro-mote the growth and appreciation of tumor cells through the waberg effect, is an important marker of tumor energy metabolism, and is a potential new tumor marker. The authors reviewed it and combed the tumor.
| [1] | 张明鑫. 消化道早癌如何防治[J]. 家庭医药. 就医选药, 2021(11): 32-33. |
| [2] | Mu？oz-Colmenero, A., Fernán-dez-Suárez, A., Fatela-Cantillo, D., et al. (2015) Plasma Tumor M2-Pyruvate Kinase Levels in Different Cancer Types. Anticancer Research, 35, 4271-4276. |
| [3] | Christofk, H.R., Heiden, M., Harris, M.H., et al. (2008) The M2 Splice Iso-form of Pyruvate Kinase Is Important for Cancer Metabolism and Tumour Growth. Nature, 452, 230-233. https://doi.org/10.1038/nature06734 |
| [4] | Munoz-Colmenero, A., Fernandez-Suarez, A., Fatela-Cantillo, D., et al. (2015) Plasma Tumor M2-Pyruvate Kinase Levels in Different Cancer Types. Anticancer Research: International Jour-nal of Cancer Research and Treatment, 35, 4271-4276. |
| [5] | Dong, G.C., Mao, Q.X., Xia, W.J., et al. (2016) PKM2 and Cancer: The Function of PKM2 beyond Glycolysis. Oncology Letters, 11, 1980-1986. https://doi.org/10.3892/ol.2016.4168 |
| [6] | Rihan, M., Nalla, L.V., Dharavath, A., et al. (2019) Pyruvate Kinase M2: A Metabolic Bug in Re-Wiring the Tumor Microenvironment. Cancer Microenvironment, 12, 149-167. https://doi.org/10.1007/s12307-019-00226-0 |
| [7] | 高洋, 孙昭, 白春梅. 丙酮酸激酶M2在胃癌中的作用[J]. 协和医学杂志, 2021, 12(2): 227-231. |
| [8] | Chen, M., David, C.J. and Manley, J.L. (2012) Concentration-Dependent Control of Pyruvate Kinase M Mutually Exclusive Splicing by hnRNP Proteins. Nature Structural & Molecular Biology, 19, 346-354.
https://doi.org/10.1038/nsmb.2219 |
| [9] | David, C.J., Chen, M., Assanah, M., et al. (2010) HnRNP Proteins Con-trolled by c-Myc Deregulate Pyruvate Kinase mRNA Splicing in Cancer. Nature, 463, 364-368. https://doi.org/10.1038/nature08697 |
| [10] | 孙倩. M2型丙酮酸激酶(PKM2)在肿瘤代谢和发生中的作用[J]. 基础医学与临床, 2012, 32(5): 462-467. |
| [11] | Novotny, I., Dite, P., Dastych, M., et al. (2008) Tumor Marker M2-Pyruvate-Kinase in Differential Diagnosis of Chronic Pancreatitis and Pancreatic Cancer. Hepato-Gastroenterology, 55, 1475-1477. |
| [12] | Landt, S., Jeschke, S., Koeninger, A., et al. (2010) Tumor-Specific Correlation of Tumor M2 Py-ruvate Kinase in Pre-Invasive, Invasive and Recurrent Cervical Cancer. Anticancer Research, 30, 375. |
| [13] | Levic, K., Bulut, O., Hesselfeldt, P., et al. (2013) The Outcome of Rectal Cancer after Early Salvage TME Following TEM Com-pared with Primary TME: A Case-Matched Study. Techniques in Coloproctology, 17, 397-403.
https://doi.org/10.1007/s10151-012-0950-2 |
| [14] | 杨刚, 唐丽娟. 血清TuM2-PK、CEA、CA19-9和CA72-4对结肠癌的筛查价值[J]. 检验医学与临床, 2017, 14(1): 35-36+39. |
| [15] | 杜宇, 阳振曦, 苏建荣. 胶体金法粪便检测TU M2PK在结直肠癌诊断中的价值[J]. 空军医学杂志, 2019, 35(3): 229-232. |
| [16] | 张丹. 肿瘤M2型丙酮酸激酶检测在结肠癌诊断中的临床价值[J]. 中国卫生标准管理, 2021, 12(6): 95-98. |
| [17] | 王俊伟, 金心富, 卢凯. 腹腔镜切除术配合FOLFOX4新辅助化疗对直肠癌患者血清FAS、Tu M2-PK及T细胞亚群的影响[J]. 临床和实验医学杂志, 2019, 18(9): 981-985. |
| [18] | Li, S., Ji, X., Wang, R., et al. (2019) Follicle-Stimulating Hormone Promoted Py-ruvate Kinase Isozyme Type M2-Induced Glycolysis and Proliferation of Ovarian Cancer Cells. Archives of Gynecology and Obstetrics, 299, 1443-1451.
https://doi.org/10.1007/s00404-019-05100-4 |
| [19] | Zhou, Z.F., Li, M., Zhang, L., et al. (2018) Oncogenic Ki-nase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-Like Cells. Cancer Research, 78, 2248-2261.
https://doi.org/10.1158/0008-5472.CAN-17-2726 |
| [20] | Rui, H.Y., et al. (2019) Pyruvate Kinase M2 Contributes to Cell Growth in Gastric Cancer via Aerobic Glycolysis. Pathology, Research and Practice, 215, Article ID: 152409. https://doi.org/10.1016/j.prp.2019.04.001 |
| [21] | 翁映玲. 血清TuM2-PK、TK1、HER-2表达水平对直肠癌的诊断价值[J]. 河南医学研究, 2018, 27(10): 1795-1797. |
| [22] | 樊晓静, 史志涛, 孙昕. TuM2-PK、TK1、CEA、CA19-9和CA72-4在结肠癌患者诊断中的意义[J]. 中国老年学杂志, 2019, 39(4): 814-816. |
| [23] | 齐容容, 刘卫华, 常娅洁. 血清CEA和CA199及TuM2-PK水平联合检测对结肠癌诊断效能影响[J]. 社区医学杂志, 2021, 19(22): 1362-1365. |
| [24] | 于同波, 刘程, 周珍娟. 血清CEA、CA125、CA199及血浆M2-PK联合检测胃癌的诊断价值研究[J]. 中国实用医药, 2018, 13(24): 3-5. |
| [25] | 钟世洪, 成志烜, 王卓. 血清CEA CA199 CA125及血浆M2-PK联合检测在胃癌诊断中的临床研究[J]. 基层医学论坛, 2018, 22(1): 1-2. |
| [26] | Wang, C., Jiang, J., Ji, J., et al. (2017) PKM2 Promotes Cell Migration and Inhibits Autophagy by Mediating PI3K/ AKT Activation and Contributes to the Ma-lignant Development of Gastric Cancer. Scientific Reports, 7, Article No. 2886. https://doi.org/10.1038/s41598-017-03031-1 |
| [27] | 陈洈伟. 丙酮酸激酶M2蛋白与胃癌的临床病理联系[J]. 中国继续医学教育, 2020, 12(23): 102-104. |
| [28] | 徐明静, 芦东徽, 高世乐, 等. 原发性肝癌组织中PKM2、COX2及IAPs的表达及其与放疗敏感性的关系分析[J]. 安徽医科大学学报, 2021, 56(10): 1612-1616. |
| [29] | 马欢, 芦东徽, 徐滨, 等. 肝癌组织中PKM2表达及与放疗敏感性的关系[J]. 临床与实验病理学杂志, 2020, 36(2): 192-194. |
| [30] | 徐强, 宋杰, 许敏, 等. M2型丙酮酸激酶同工酶表达对肝细胞癌化疗敏感性的影响[J].介入放射学杂志, 2019, 28(9): 855-860. |
| [31] | 赵睿. M2型丙酮酸激酶(PKM2)与肝细胞癌恶性增生及预后相关的功能研究[D]: [博士学位论文]. 兰州: 兰州大学, 2019. |
| [32] | Bandara, I.A., Baltatzis, M., Sanyal, S., et al. (2018) Evaluation of Tu-mor M2-Pyruvate Kinase (Tumor M2-PK) as a Biomarker for Pancreatic Cancer. World Journal of Surgical Oncology, 16, 56.
https://doi.org/10.1186/s12957-018-1360-3 |
| [33] | Goonetilleke, K.S., Mason, J.M., Siriwardana, P., et al. (2007) Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary Cancer: Evidence for a Novel Biological Marker of Adverse Prognosis. Pancreas, 34, 318-324. https://doi.org/10.1097/MPA.0b013e31802ee9c7 |
| [34] | 王金, 赵一洁, 尚培中, 等. 胆管癌患者血清肿瘤型M2丙酮酸激酶水平变化及临床意义[J]. 中国普通外科杂志, 2020, 29(2): 220-227. |
| [35] | 柴浩, 熊新魁, 孙道一, 等. PKM2基因对胆管细胞癌迁移、侵袭及增殖的影响[J]. 南京医科大学学报(自然科学版), 2015, 35(5): 615-621. |
| [36] | Li, Y.G. and Zhang, N. (2009) Clinical Significance of Serum Tumour M2-PK and CA19-9 Detection in the Diagnosis of Cholangiocarcinoma. Digestive and Liver Disease, 41, 605-608. https://doi.org/10.1016/j.dld.2008.11.010 |
| [37] | 张汗磊, 王松, 陈思, 等. 粪便肿瘤M2型丙酮酸激酶在结直肠癌和腺瘤性息肉中的诊断价值[J]. 医学信息, 2021, 34(12): 78-81. |
| [38] | Bond, A.D., Burkitt, M.D., Sawbridge, D., et al. (2016) Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenoma-tous Neoplasia in a Secondary Care Cohort. The Journal of Gastrointestinal and Liver Diseases, 25, 71-77. https://doi.org/10.15403/jgld.2014.1121.251.m2p |
